EUCTR2016-002794-35-PT进行中（未招募）1 期
A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafeniband trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600 mutant melanoma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 538
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Part 1: Safety run-in
- •Histologically confirmed, unresectable or metastatic melanoma with
- •BRAF V600 mutation
- •Aspartate transaminase (AST) < 2.5× ULN and Alanine transaminase
- •(ALT) < 2.5× ULN
- •ECOG performance status = 1
- •Part 2: Biomarker cohort
- •Histologically confirmed, unresectable or metastatic melanoma with
- •BRAF V600 mutation
- •At least two cutaneous or subcutaneous or nodal lesions for tumor
- •sample collection
- •ECOG performance status = 2
- •Part 3: Double-blind, randomized, placebo-controlled part
- •Histologically confirmed, unresectable or metastatic melanoma with
- •BRAF V600 mutation
- •ECOG performance status = 2
- •Other protocol-defined Inclusion criteria may apply.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 409
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 129
排除标准
- •Part 1: Safety run-in
- •Subjects with uveal or mucosal melanoma
- •Any history of CNS metastases
- •Prior systemic anti-cancer treatment for unresectable or metastatic
- •Prior loco-regional treatment for unresectable or metastatic melanoma in the last 6 month
- •Prior neoadjuvant and/or adjuvant therapy for melanoma completed
- •less than 6 months
- •Radiation therapy within 4 weeks prior to start of study treatment
- •Active, known, suspected or a documented history of autoimmune
- •Parts 2 & 3: Biomarker cohort & double-blind, randomized, placebocontrolled part
- •Subjects with uveal or mucosal melanoma
- •Clinically active cerebral melanoma metastasis
- •Prior systemic anti-cancer treatment for unresectable or metastatic
- •Prior loco-regional treatment for unresectable or metastatic melanoma in the last 6 month
- •Prior neoadjuvant and/or adjuvant therapy for melanoma completed
- •less than 6 months
- •Radiation therapy within 4 weeks prior to start of study treatment
- •Active, known, suspected or a documented history of autoimmune
- •Other protocol-defined Exclusion may apply.
研究者
相似试验
进行中（未招募）
1 期
Study of efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated locally advanced or metastatic non-squamous and squamous NSCLC subjectsstages AJCC v. 8 IIIB (not eligible for definite chemoradiation therapy) or stage IV (metastatic) non-small cell lung cancer (NSCLC)MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001547-32-FRovartis Pharma AG627
已完成
3 期
A randomized, double-blind, placebo-controlled, phase III multicenter study of subcutaneous secukinumab (150 mg) with and without a subcutaneous loading regimen to assess efficacy, safety, and tolerability up to 2 years in patients with active ankylosing spondylitisNL-OMON44029ovartis15
进行中（未招募）
1 期
A phase 2b study to assess the efficacy and safety of OBE2109 in subjects with endometriosis.Treatment of Endometriosis-Associated PainMedDRA version: 20.0Level: SOCClassification code 10038604Term: Reproductive system and breast disordersSystem Organ Class: 10038604 - Reproductive system and breast disordersMedDRA version: 20.0Level: LLTClassification code 10014788Term: Endometriosis related painSystem Organ Class: 10038604 - Reproductive system and breast disordersMedDRA version: 20.0Level: PTClassification code 10014778Term: EndometriosisSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2016-001736-35-PLObsEva SA328
已完成
2 期
A randomized, double-blind, placebo-controlled, phase II, cross-over clinical trial evaluating the efficacy and safety of KVD900, an oral plasma kallikrein inhibitor, in the on-demand treatment of angioedema attacks in adult subjects with hereditary angioedema type I or IIHereditary Angioedema Type I or IIswelling of tissues10003816NL-OMON48423KalVista Pharmaceuticals Limited15
尚未招募
2 期
A randomized, double-blind, placebo-controlled, phase 2a study of the efficacy, safety, and pharmacokinetics of MLN3897 in patients with rheumatoid arthritis taking methotrexate.arthritischronic joint inflammation1000381610023213NL-OMON30310Millenium Pharmaceuticals6